Anti-TNF-α therapy reduced the number of nonclassical monocytes and M1 macrophages, ameliorated the retention of platelets in spleen and liver, and increased the platelet count of ITP mice [32]. This evidence concerns the gene TNF and autoimmune thrombocytopenic purpura.